The Cystic Fibrosis Foundation practices venture philanthropy by making strategic investments in companies and technologies with the potential to treat or cure CF. We have a proven track record of accelerating the development of innovative therapies through financial investment, customized research materials, and clinical trial infrastructure.
Site Search
The Cystic Fibrosis Foundation offers a broad range of funding opportunities to support academic and industry investigators to pursue research on topics relevant to cystic fibrosis. Each application undergoes a rigorous scientific review process before funding is allocated.
This program is intended to facilitate research that will contribute to the development of new therapies or therapeutic strategies to treat cystic fibrosis with an emphasis on advancing CFTR gene repair and replacement approaches.
mRNA therapy is one way to deliver the correct genetic instructions to cells, which would allow them to make functional CFTR protein regardless of an individual’s CF mutations.
Cystic fibrosis is caused by mutations in both copies of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Scientists are examining whether it is possible to correct the mutations through a process called gene editing.
Through efficient study design, optimized clinical trial execution, and high-quality data, the Therapeutics Development Network (TDN) helps speed the delivery of new and better therapies to people with cystic fibrosis.
We offer awards for cystic fibrosis research and for professional development and training. Below is a list of current and upcoming funding opportunities.
Cystic fibrosis is caused by mutations in the gene responsible for producing the cystic fibrosis transmembrane conductance regulator (CFTR) protein. For this reason, scientists are exploring ways to provide a correct copy of the gene to treat CF.